After 1 vaccination, 13/25 puppies exhibited a 4-fold or greater increase in CPV SN titer (seroconversion). The group of vaccinates received 3 doses, with vaccinations administered 3 weeks apart beginning at 6 weeks of age.
Vanguard serial numbers trial#
2,3 A clinical trial was conducted with fifty 6-week-old puppies. Serum neutralization titers as low as 1:4 have been shown by others to interfere with active immunization using conventional modified live vaccines.
demonstrated that 3 doses of the vaccine with increased CPV virus titer can overcome serum neutralization (SN) titers associated with maternal antibody.
Although this CPV vaccine virus was found occasionally and in low titers in the feces of vaccinated dogs, testing demonstrated that the vaccine master seed did not revert to virulence following 6 consecutive backpassages in susceptible dogs.
Vanguard serial numbers plus#
The CPV virus in Vanguard Plus 5 shares a characteristic with other live CPV vaccine strains in that the vaccine virus may be present in the feces following administration. Product safety was further demonstrated by a backpassage study which included oral administration of multiple doses of the vaccine strain to susceptible dogs, all of whom remained normal. It was shown safe with minimal reactions in laboratory tests and in clinical trials under field conditions. The CPV fraction in Vanguard Plus 5 was subjected to comprehensive safety and efficacy testing at Zoetis Inc. Canine adenovirus type 2 challenge virus was not recovered from CAV-2-vaccinated dogs in tests conducted at Zoetis Inc. 1 Although conventional CAV-1 (ICH) vaccines cross-protect against CAV-2, they may not prevent subclinical infection and spread of the CAV-2 agent. demonstrated that the CAV-2 strain used in Vanguard vaccines not only protects against ICH, but against CAV-2 respiratory disease as well. In addition, the CAV-2 strain used in Vanguard vaccines has been specially selected for freedom from oncogenic properties characteristic of adenoviruses. It has been demonstrated that CAV-2 vaccine cross-protects against ICH caused by CAV-1. showed it to be safe with minimal reactions in dogs as young as 6 weeks of age under normal usage conditions.
Extensive field safety trials conducted by Zoetis Inc. SAFETY AND EFFICACY: Laboratory evaluation demonstrated that Vanguard Plus 5 aided in preventing CD, ICH, CAV-2 respiratory disease, CPI, and CPV, and that no significant immunological interference existed among the vaccine fractions. Vanguard Plus 5 is packaged in freeze-dried form with inert gas in place of vacuum. Some puppies in the field may have higher levels of maternal antibodies than those evaluated in our pivotal efficacy study. The CPV fraction is high titer (>10 7.0 TCID 50/dose) and was attenuated by low passage (35 passes from the canine isolate with a maximum of 2 additional passes allowed for production) in the canine cell line which gives it the immunogenic properties capable of overriding maternal antibody interference at the levels indicated below. Vanguard Plus 5 contains attenuated strains of CD virus, CAV-2, CPI virus, and CPV propagated in an established canine cell line. PRODUCT DESCRIPTION: Vanguard Plus 5 is for vaccination of healthy dogs 6 weeks of age or older as an aid in preventing canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, and canine parvoviral enteritis caused by canine parvovirus (CPV). Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine
0 kommentar(er)
